Castle Biosciences, Inc. — FY 2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022; filed February 28, 2023. This is an annual report, not a standalone Q4 earnings report. The filing gives Q4 test-report volumes but does not provide a clear Q4 revenue or profit figure in the supplied text.
Business context
Castle Biosciences is a commercial-stage diagnostics company. Revenue is primarily generated by DecisionDx-Melanoma, with other tests covering skin cancers, uveal melanoma, Barrett’s esophagus and mental health. The company completed its AltheaDx acquisition in April 2022, adding IDgenetix; it acquired Cernostics in December 2021 and Myriad MyPath Laboratory in May 2021.
Key financial metrics
| Metric | FY 2022 | FY 2021 |
|---|---|---|
| Net revenue | $137.0 million | $94.1 million |
| Gross margin | $96.8 million; 70.6% | $76.3 million; 81.1% |
| Operating loss | $72.9 million | $40.1 million |
| Net loss | $67.1 million | $31.3 million |
| Net cash used in operating activities | $41.7 million | $19.0 million |
| Cash and cash equivalents, year-end | $122.9 million | $329.6 million |
| Marketable investment securities, year-end | $135.7 million | — |
Revenue increased 45.7%. Test reports rose to 44,419 from 28,145, including 27,803 DecisionDx-Melanoma reports, 5,967 DecisionDx-SCC reports, 2,128 TissueCypher reports and 3,249 IDgenetix reports. The company reported no material outstanding borrowings; it had lease liabilities and finance leases.
Changes and notable items
- Dermatologic revenue grew to $124.8 million from $85.8 million; other-test revenue rose to $12.2 million from $8.3 million.
- Cost of sales more than doubled, while R&D rose 51.5% and SG&A rose 64.9%. Higher laboratory and commercial staffing, acquisition-related costs, and stock-based compensation contributed to expense growth.
- Gross margin fell 10.5 percentage points, reflecting higher staffing and acquired-intangible amortization, as well as prior-period revenue adjustments.
- A $18.3 million gain from remeasurement of Cernostics contingent consideration reduced operating expenses; the earnout was not payable because its milestones were not met. AltheaDx’s 2022 milestones also were not met; up to $57.5 million of potential payments remained for 2023–2024, including a possible 2023 catch-up payment.
- Operating cash outflow increased, and cash and cash equivalents declined substantially. Much of the investing outflow reflected purchases of marketable securities, not solely operating consumption.
Outlook, risks and contingencies
Management said cash, marketable securities and anticipated product revenue should fund operations for at least 12 months and the foreseeable future, while noting estimates depend on assumptions and additional capital may be needed. No formal revenue or earnings guidance is provided. The company expects continued spending on commercialization, evidence development, laboratory capacity and pipeline programs; it expects near-term gross margin to remain lower as it invests in capacity ahead of volume and reimbursement.
The company targeted launch of a genomic test for inflammatory skin disease by the end of 2025; its 4,800-patient IDENTITY study had 507 patients enrolled and 54 committed sites as of February 2023. In February 2023, it suspended the clinical offering of DiffDx-Melanoma, citing improved MyPath Melanoma performance and a decision to stop offering both tests.
Key risks include dependence on a concentrated payor base (Medicare represented 53% of 2022 revenue and one commercial payor 12%), reimbursement and coverage uncertainty, revenue estimates affected by variable consideration, persistent losses, regulatory uncertainty for laboratory-developed tests, and execution/integration risks. The company also cited inflation, supply constraints, competition and reliance on key personnel and suppliers. It reported no pending or threatened litigation believed likely to have a material adverse effect. The auditor issued unqualified opinions on the financial statements and internal control over financial reporting.
Investor facts to verify
- Whether test-volume growth converts into collected revenue, given reimbursement concentration, claim appeals and variable-consideration estimates.
- Progress on Medicare and commercial coverage, including the DecisionDx-SCC pricing process and the IDgenetix billing-code change.
- Cash use, operating-loss trajectory, and the funding impact of commercial expansion, R&D and remaining AltheaDx milestone obligations.
- Whether new products and acquired businesses gain adoption and reimbursement, and whether the inflammatory skin disease test meets its development and launch timeline.
- Potential dilution and future expense from equity compensation: 2022 stock-based compensation was $36.3 million, with $131.6 million of unrecognized compensation cost at year-end.